MHE Question of the Week: Will the ACA Help Biden and the Democrats?
The 14th anniversary of the Affordable Care Act was this past Saturday.
Some background
President Joe Biden and other Democrats celebrated the 14th anniversary of President Barack Obama signing the Affordable Care Act (ACA) into law on Saturday with a flurry of online posts and images. “14 years later, the Affordable Care Act is still a very big deal,” Biden posted on X, a coy reference to his profane, hot mic version of the same expression at the bill’s signing. Although Biden is running behind Donald Trump in many polls, Biden and the Democrats believe that ACA will be a political asset this fall and could turn the election in their favor. KFF polling shows the law is viewed favorably overall, although approximately two-thirds (67%) of Republicans view it unfavorably and 39% say they want it repealed. Trump has focused on immigration and Biden’s age at his rallies, but in a Truth Social post late last year he said that “the cost of Obamacare is out of control” and that he was seriously looking at alternatives.
Will the Affordable Care Act Help Biden and the Democrats in the November 2024 Election?
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More
